Driving vision in patients with neovascular AMD in anti-VEGF treatment.
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ administration & dosage
Automobile Driving
Female
Follow-Up Studies
Humans
Intravitreal Injections
Male
Ranibizumab
/ administration & dosage
Retrospective Studies
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
Wet Macular Degeneration
/ diagnosis
age-related macular degeneration
anti-VEGF
driver’s license
driving vision
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
05
02
2021
received:
17
08
2020
accepted:
12
02
2021
pubmed:
6
3
2021
medline:
28
1
2022
entrez:
5
3
2021
Statut:
ppublish
Résumé
To report real-world experiences on driving vision in patients with neovascular age-related macular degeneration (AMD) undergoing intravitreal anti-VEGF treatment. Retrospective cohort study of treatment-naïve patients with neovascular AMD commenced in anti-VEGF treatment (n = 416) and followed for 4 years in a pro re nata treatment regimen. Monocular best-corrected visual acuity (BCVA) measured using ETDRS was performed on the treatment eye at all visits and on the fellow eye at baseline, every 6 months, and upon any patient-reported change in vision. Driving vision was defined as BCVA in the best-seeing eye of ≥70 ETDRS letters (equivalent to ≥0.5 Snellen) corresponding to the minimum BCVA required in many countries. Driving vision was present in 280 patients (67%) and was sustained in 86%, 74%, 65% and 59% of the patients at 1, 2, 3 and 4 years, respectively. Lower BCVA in the best-seeing eye predicted loss of driving vision. In patients without driving vision at baseline, driving vision was regained in 29%, 36%, 39% and 41% of the patients at 1, 2, 3 and 4 years, respectively; but only 35% sustained driving vision after the first year. Lower age and higher BCVA in best-seeing eye predicted regain of driving vision. Driving vision can be sustained in the majority of the patients if they have driving vision at baseline. This study provides important prognostic information for patients with neovascular AMD.
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1360-e1365Informations de copyright
© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Age-Related Eye Disease Study 2 Research Group (2013): Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309: 2005-2015.
Bloch SB, Larsen M & Munch IC (2012): Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol 153: 209-213.
Brynskov T, Munch IC, Larsen TM, Erngaard L & Sørensen TL (2020): Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol 98: 132-138.
Chandra S, Rasheed R, Menon D et al. (2020): Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration. Eye (Lond) 35(2): 409-417.[ePub ahead of Print]. https://doi.org/10.1038/s41433-020-0851-y.
Edwards JD, Perkins M, Ross LA & Reynolds SL (2009): Driving status and three-year mortality among community-dwelling older adults. J Gerontol A Biol Sci Med Sci 64: 300-305.
Fonda SJ, Wallace RB & Herzog AR (2001): Changes in driving patterns and worsening depressive symptoms among older adults. J Gerontol B Psychol Sci Soc Sci 56: S343-351.
Garweg JG, Zirpel JJ, Gerhardt C & Pfister IB (2018): The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefes Arch Clin Exp Ophthalmol 256: 823-831.
Høeg TB, Ellervik C, Buch H, La Cour M, Klemp K, Kvetny J, Erngaard D & Moldow B (2016): Danish rural eye study: epidemiology of adult visual impairment. Ophthalmic Epidemiol 23: 53-62.
Horner F, Lip PL, Clark H, Chavan R, Sarmad A & Mushtaq B (2019): Real-world visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: an 8-year observational cohort (AMD8). Clin Ophthalmol 13: 2461-2467.
Hugosson M & Ekström C. (2020): Prevalence and risk factors for age-related cataract in Sweden. Ups J Med Sci 125(4): 311-315.[ePub ahead of Print]. https://doi.org/10.1080/03009734.2020.1802375.
Kolko M, Horwitz A, Thygesen J, Jeppesen J & Torp-Pedersen C (2015): The prevalence and incidence of glaucoma in Denmark in a fifteen year period: a nationwide study. PLoS One 10: e0132048.
Lorentzen TD, Subhi Y & Sørensen TL (2018a): Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment-naïve exudative age-related macular degeneration. Acta Ophthalmol 96: 475-480.
Lorentzen TD, Subhi Y & Sørensen TL (2018b): Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration: systematic review and meta-analysis. Retina 38: 2363-2371.
Mitchell P, Liew G, Gopinath B & Wong TY (2018): Age-related macular degeneration. Lancet 392: 1147-1159.
Mobility and Transport, European Union, Accessed on 11/08/2020. URL: https://ec.europa.eu/transport/road_safety/specialist/knowledge/old/safety_versus_mobility_and_quality_of_life/the_effects_of_driving_cessation_en
Sedeh FB, Scott DAR, Subhi Y & Sørensen TL (2017): Prevalence of neovascular age-related macular degeneration and geographic atrophy in Denmark. Dan Med J 64: A5422.
Sengupta S, van Landingham SW, Solomon SD, Do DV, Friedman DS & Ramulu PY (2014): Driving habits in older patients with central vision loss. Ophthalmology 121: 727-732.
Starr MR, Kung FF, Mejia CA, Bui YT & Bakri SJ. (2019): Ten-year follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Retina 40(9): 1665-1672.[ePub ahead of Print]. https://doi.org/10.1097/IAE.0000000000002668.
Visual Standards for Driving in Europe, European Council of Optometry and Optics. Accessed on 11/08/2020. URL: https://www.ecoo.info/wp-content/uploads/2017/01/Visual-Standards-for-Driving-in-Europe-Consensus-Paper-January-2017....pdf
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY & Wong TY (2014): Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2: e106-116.